Thursday, 24 January 2019
BREAKING NEWS

Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low …

World Health Organization, Geneva, Switzerland (G.R., S.L.N.)

Financial Support: Financial support for the development of this synopsis came from the World Health Organization budget.

Disclosures: Dr. Roglic is an employee of the World Health Organization, where she manages the process of guideline development in the field of diabetes. Dr. Norris reports stock ownership in Teva Pharmaceutical Industries, Athenahealth, and CVS Health. She is an employee of the World Health Organization, where she helps to oversee the quality of WHO guidelines. She is also a member of the GRADE Working Group. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-1149.

Editors’ Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Proctor & Gamble, Pfizer, and Johnson & Johnson.

Corresponding Author: Gojka Roglic, MD, MSc, World Health Organization, 20 Avenue Appia, Geneva 1211, Switzerland; e-mail, [email protected].

Current Author Addresses: Drs. Roglic and Norris: World Health Organization, 20 Avenue Appia, Geneva 1211, Switzerland.

Author Contributions: Analysis and interpretation of the data: G. Roglic, S.L. Norris.

Drafting of the article: G. Roglic.

Critical revision of the article for important intellectual content: S.L. Norris.

Final approval of the article: G. Roglic, S.L. Norris.

Source: http://annals.org/aim/fullarticle/2698900/medicines-treatment-intensification-type-2-diabetes-type-insulin-type-1

« »